Education Guide · Updated March 2026

Compounded vs Brand-Name GLP-1: What You Need to Know in 2026

Compounded semaglutide costs $149-$199 per month. Brand-name Wegovy costs $1,349 per month at list price. They contain the same active ingredient. But they are not the same product. And in 2026, the legal ground under compounded GLP-1s is shifting fast. Here is what you need to understand before choosing.

The Basics: What Is Compounding?

Compounding is when a licensed pharmacy takes a drug’s active ingredient and formulates it into a medication in-house, rather than using the manufacturer’s product. This is legal under FDA rules (Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act) and has been common in medicine for decades.

For GLP-1 medications, this means a compounding pharmacy takes semaglutide or tirzepatide as a raw ingredient and creates an injectable (or oral) formulation. The result is a medication with the same active molecule as Wegovy or Zepbound, but produced by a smaller pharmacy rather than Novo Nordisk or Eli Lilly.

Price Comparison

The cost difference is dramatic:

Brand-name manufacturers have cut self-pay prices significantly in 2025-2026. Novo Nordisk’s Wegovy pill launched at $149/month, and Eli Lilly’s LillyDirect offers Zepbound vials at $299-$499/month. These self-pay options have narrowed the price gap with compounded versions.

For a full breakdown of all pricing options, see our cheapest GLP-1 guide. If you have employer-sponsored coverage, our insurance coverage guide walks through the prior auth process.

The Key Differences

Manufacturing Standards

Brand-name medications are produced in FDA-inspected facilities following strict Current Good Manufacturing Practices (cGMP). Every batch is tested for potency, purity, and sterility. The formulation has been through Phase 1, 2, and 3 clinical trials with thousands of participants.

Compounded medications vary by pharmacy type:

• 503B outsourcing facilities (like Belmar Pharmacy, used by MEDVi) follow cGMP standards and are subject to FDA inspection. They perform batch-level testing including HPLC (High-Performance Liquid Chromatography) potency analysis. This is the higher quality tier.

• 503A pharmacies are traditional compounding pharmacies that fill individual prescriptions. They are regulated by state boards of pharmacy, not directly by the FDA. Quality standards vary significantly from pharmacy to pharmacy.

Quality Concerns

Novo Nordisk has publicly claimed that its testing of compounded semaglutide from various pharmacies found impurities as high as 86% in injectable products and 75% in oral formulations. These numbers are alarming if accurate, but they come from a company with a financial interest in discrediting compounded competitors.

Independent quality data on compounded GLP-1s is limited. A 503B facility with HPLC batch testing (like Belmar) provides more assurance than a 503A pharmacy with less rigorous testing. If you choose compounded, ask your provider which pharmacy they use and whether they can provide batch testing results.

Clinical Evidence

All major clinical trial data (SURMOUNT-1, STEP 1, SURMOUNT-5) comes from brand-name medications. For a detailed look at how Mounjaro compares to Ozempic in those trials, see our head-to-head comparison. No large-scale clinical trials have been conducted on compounded semaglutide or tirzepatide. The assumption is that the same active ingredient produces the same effect, and this is generally true in pharmacology. But the specific formulation, inactive ingredients, and delivery mechanism can affect absorption and bioavailability.

Most patients report similar results on compounded versus brand-name products. But “most patients report” is not the same as “clinical trials prove.”

The Legal Situation in 2026

This is the most important section. The legal ground has shifted dramatically.

Semaglutide

• February 2025: FDA declared the semaglutide shortage resolved
• April 2025: Enforcement discretion ended for 503A pharmacies compounding semaglutide
• May 2025: Enforcement discretion ended for 503B facilities
• September 2025: FDA sent warning letters to multiple entities for compounding promotion
• February 2026: Novo Nordisk sued Hims for patent infringement covering both injectable and oral compounded semaglutide (U.S. Patent No. 8,129,343, valid through December 2031)

Tirzepatide

• October 2024: FDA declared the tirzepatide shortage resolved
• February 2025: Enforcement discretion ended for 503A pharmacies
• March 2025: Enforcement discretion ended for 503B facilities
• May 2025: Federal court upheld FDA’s decision to remove tirzepatide from the shortage list
• September 2025: FDA sent warning letters to 50+ entities for GLP-1 compounding issues

What This Means

Routine compounding of “essentially copies” of FDA-approved semaglutide and tirzepatide is no longer permitted under the shortage exception. However, compounding may continue under Section 503A when a prescriber documents that a patient’s specific medical needs cannot be met by commercially available products (the “clinical difference” argument).

Platforms like MEDVi and SkyRx continue to operate using this legal framework. Whether this survives increased FDA enforcement and ongoing litigation is uncertain.

Bottom line: If you start on compounded GLP-1 medication today, understand that the product may not be available indefinitely. Have a backup plan (brand-name, insurance coverage, or manufacturer self-pay options).

When to Choose Brand-Name

Choose brand-name if:

• Your insurance covers GLP-1 medications (many commercial plans do, with prior authorization)
• You want the product that went through rigorous clinical trials
• You want regulatory certainty (brand-name products are not going anywhere)
• You are concerned about quality and purity
• You can afford manufacturer self-pay pricing ($149-$499/month through LillyDirect or NovoCare)

Where to get brand-name: Ro offers Wegovy (pill and injectable) and Zepbound with insurance concierge. Calibrate works exclusively with brand-name medications through insurance. You can also get brand-name prescriptions through your primary care doctor.

When to Choose Compounded

Choose compounded if:

• You do not have insurance coverage for GLP-1s
• You cannot afford brand-name self-pay pricing
• You are comfortable with the regulatory uncertainty
• Your provider uses a reputable 503B pharmacy with batch testing
• You understand that compounded products have not been through the same clinical trials

Where to get compounded: Hims ($199/mo for semaglutide), MEDVi ($179-$499/mo for semaglutide or tirzepatide), Eden ($179/mo for semaglutide), SkyRx ($299/mo for both).

How to Verify Pharmacy Quality

If you choose compounded, ask these questions:

1. Is the pharmacy a 503A or 503B facility? 503B is the higher standard (FDA-inspected, cGMP requirements).
2. Do they perform HPLC potency testing on every batch? This verifies the active ingredient is present at the correct concentration.
3. Is the pharmacy FDA-registered? You can check the FDA’s registration database.
4. Has the pharmacy received any FDA warning letters? Search the FDA’s warning letter database.
5. Is the pharmacy accredited by PCAB (Pharmacy Compounding Accreditation Board)? This is an additional quality marker.

Not every telehealth platform will answer these questions directly. That opacity itself is a data point.

The Bottom Line

The gap between compounded and brand-name GLP-1s is narrowing. Manufacturer self-pay prices have dropped significantly (Wegovy pill at $149/month, Zepbound at $299/month). The legal environment for compounded versions is getting more hostile. And quality concerns, while hard to verify independently, are real.

If you can afford brand-name (either through insurance or manufacturer self-pay), that is the safer choice in 2026. If cost is the primary barrier, compounded medications from a reputable 503B pharmacy remain a reasonable option, with the understanding that availability could change if the FDA tightens enforcement or new lawsuits reshape the market. Whichever you choose, be prepared for side effects during titration and track your body composition to monitor muscle loss alongside fat loss.

Compare all your options in our provider directory. Providers vary by state, so check California or Texas availability if those are your states.

FAQ

Are compounded GLP-1 medications safe?

When produced by a reputable 503B outsourcing facility following cGMP standards with batch-level potency testing, compounded GLP-1s are generally considered safe. However, they have not gone through the same clinical trials as brand-name products, and quality varies significantly between pharmacies. Novo Nordisk claims to have found impurities up to 86% in some compounded samples, though this data has not been independently verified.

Is compounded semaglutide still legal in 2026?

The FDA declared the semaglutide shortage resolved in February 2025, ending the broad legal basis for compounding. However, 503A pharmacies may still compound semaglutide when a prescriber documents a “clinical difference” for a specific patient that cannot be met by commercially available products. The legal situation is actively evolving, with Novo Nordisk suing providers like Hims for patent infringement.

Is compounded tirzepatide still available?

Yes, but under increasing legal pressure. The FDA resolved the tirzepatide shortage in October 2024, and a federal court upheld that decision in May 2025. Platforms like MEDVi continue to offer compounded tirzepatide through 503B pharmacies using patient-specific prescriptions. Long-term availability is uncertain.

What is the difference between a 503A and 503B pharmacy?

503A pharmacies are traditional compounding pharmacies regulated by state boards. They fill individual prescriptions based on patient-specific orders. 503B outsourcing facilities are FDA-registered, follow cGMP standards (similar to drug manufacturers), and can produce larger batches for distribution. 503B facilities generally have higher quality standards and more rigorous testing.

Should I switch from compounded to brand-name?

If your insurance covers brand-name GLP-1s, switching reduces regulatory risk and quality concerns. If you are paying cash, compare the total cost: brand-name Wegovy pill is $149-$299/month through Ro, and Zepbound is $299-$499/month through LillyDirect. These prices are now close to compounded options. The price premium for brand-name has shrunk significantly in 2026.

Related

Guides:

• Cheapest GLP-1 Online · Insurance Coverage · Side Effects
• Mounjaro Dosage Guide · Oral vs Injectable · Exercise and Muscle
• Compounded vs Brand-Name · Without Insurance

Provider Reviews: Ro · Hims · MEDVi · Found · Calibrate

Compare: All Providers · Best GLP-1 Programs · All Guides